Flagship Harbor Advisors’s Fate Therapeutics FATE Stock Holding History

Flagship Harbor Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-857	Closed	-$34K	–	914
2020 Q3	$34K	Hold	857	–	–	﹤0.01%	967
2020 Q2	$29K	Buy	857 +100	+13%	+$2.98K	﹤0.01%	1013
2020 Q1	$17K	Hold	757	–	–	﹤0.01%	1081
2019 Q4	$15K	Hold	757	–	–	﹤0.01%	1194
2019 Q3	$11K	Hold	757	–	–	﹤0.01%	1253
2019 Q2	$15K	Hold	757	–	–	﹤0.01%	1165
2019 Q1	$13K	Hold	757	–	–	﹤0.01%	1208
2018 Q4	$9K	Hold	757	–	–	﹤0.01%	1257
2018 Q3	$12K	Hold	757	–	–	﹤0.01%	1320
2018 Q2	$8K	Buy	+757	New	+$8.34K	﹤0.01%	1462

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Flagship Harbor Advisors's FATE Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 857 shares — an estimated $34K sold.

Flagship Harbor Advisors first reported a position in FATE in Q2 2018 and held it in 10 quarters. The position peaked at $34K in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

Flagship Harbor Advisors reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 857 Fate Therapeutics shares in Q4 2020, an estimated $34K.
Flagship Harbor Advisors first reported a position in Fate Therapeutics in Q2 2018 and held it in 10 quarters.
Flagship Harbor Advisors's Fate Therapeutics position peaked at $34K in Q3 2020.
248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.